消瘤治萎方治疗慢性萎缩性胃炎的疗效回顾性分析与网络药理学机制初探OA

Objective:To retrospectively summarize and analyze the clinical efficacy of Xiaoliu Zhiwei Formula(XLZWF)in treating chronic atrophic gastritis(CAG)and to preliminarily explore its mechanism of action.Methods:Clinical data of CAG patients from the Department of Spleen,Stomach,Liver,and Gallbladder of the Affiliated Hospital of Jiangxi University of Chinese Medicine between December 2022 and December 2024 were collected.Patients were divided into an experimental group(XLZWF)and a control group(conventional western medicine)based on different treatment methods.The gastroscope,pathology(atrophy,intestinal metaplasia,intraepithelial neoplasia),traditional Chinese medicine(TCM)syndrome score,and clinical efficacy were analyzed in both groups.Network pharmacology,bioinformatics,and molecular docking techniques were also used for preliminary exploration of its mechanism.Results:The retrospective analysis showed that after treatment,the gastroscope score,pathology score,and syndrome score in the experimental group were significantly better than those in the control group(all P<0.01).Additionally,various observation indicators improved in both groups compared to before treatment(P<0.05 or P<0.01).The total effective rates for gastroscope efficacy,pathological efficacy,syndrome efficacy,and clinical efficacy in the experimental group were 71.20%,80.30%,83.33%,and 66.67%,respectively,which were significantly higher than those in the control group(all P<0.01).Through network pharmacology analysis,118 common targets between inflammation-to-cancer transformation of CAG and XLZWF were identified.GO and KEGG enrichment analysis showed that targets were enriched in the PI3K-PKB/Akt,IL-17,FoxO,TNF,and p53 signaling pathways,and Cytoscape-related modules further identified 22 core genes.Molecular docking showed interactions between quercetin and potential core genes.Conclusion:This study preliminarily confirmed that XLZWF is superior to traditional western medicine in CAG patients.Network pharmacology analysis suggests that XLZWF may treat CAG by regulating the PI3K-PKB/Akt,IL-17,FoxO,TNF,and p53 signaling pathways,and these findings require further experimental verification.